Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ankur Shah

Interventional Cardiology Brooklyn, NY Medical Doctor

NPI 1144411745 CMS profile 51538

2051 Flatbush Ave, Brooklyn, NY 11234

Open in the dashboard

General payments

$32,538

342 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ankur Shah of Brooklyn, NY is reported in the CMS Open Payments database as having received $32,538 across 342 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,373 72
2024 General $3,176 53
2023 General $3,883 46
2022 General $3,870 42
2021 General $1,742 22
2020 General $3,353 34
2019 General $8,142 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ankur Shah
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Ankur Shah were reported at $8,373. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Ankur Shah Interventional Cardiology median Middle half National median
2019 $8,142 $1,097 $329–$3,048 $163
2020 $3,353 $473 $161–$1,480 $114
2021 $1,742 $677 $233–$1,827 $132
2022 $3,870 $978 $333–$2,724 $149
2023 $3,883 $1,136 $382–$2,986 $160
2024 $3,176 $1,181 $395–$3,326 $164
2025 $8,373 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $19,092 158 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $4,649 19 payments
  3. Cardiovascular Systems Inc. $2,142 37 payments
  4. Biotronik Inc. $1,300 12 payments
  5. Shockwave Medical, Inc $840 10 payments
  6. CVRx, Inc. $474 4 payments
  7. Bardy Diagnostics, Inc. $459 5 payments
  8. Merck Sharp & Dohme Corporation $447 22 payments
  9. Kestra Medical Technology Services, Inc. $416 4 payments
  10. Medtronic Vascular, Inc. $398 14 payments
  11. Other $2,323 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $22,534 332 payments
  2. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $4,950 2 payments
  3. Consulting Fee $4,023 1 payment
  4. Travel and Lodging $1,024 6 payments
  5. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. Omnilink Elite vascular stent system $4,969 5 payments
  2. Kerendia $4,624 18 payments
  3. DRAGONFLY OPSTAR $2,688 35 payments
  4. AVEIR Cardiac Rhythm Management $1,083 9 payments
  5. Peripheral Orbital Atherectomy System $893 17 payments
  6. Coronary Orbital Atherectomy System $765 18 payments
  7. Diamondback Peripheral $719 6 payments
  8. AVEIR Cardiac Rhythm Management $612 4 payments
  9. GALLANT $604 4 payments
  10. Accent Pacemaker $547 7 payments
  11. Other $14,382 229 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 89 drugs

Part D claims

6,405

Median for Cardiology: 2,533

Drug cost

$1,373,227

Median for Cardiology: $485,213

Branded share of claims

34.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 23 $601,515
Entresto Sacubitril/Valsartan Brand 238 $211,544
Eliquis Apixaban Brand 179 $136,351
Farxiga Dapagliflozin Propanediol Brand 187 $129,099
Xarelto Rivaroxaban Brand 98 $83,133
Brilinta Ticagrelor Brand 34 $35,316
Jardiance Empagliflozin Brand 49 $34,435
Januvia Sitagliptin Phosphate Brand 39 $31,502
Ozempic Semaglutide Brand 11 $16,606
Trulicity Dulaglutide Brand 12 $11,126

The 10 drugs with the highest cost, of 89 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$794,339

Medicare's payments for the services billed

Medicare patients

502

Average age 73

Services billed

5,703

315 women, 187 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 73%
Ischemic heart disease 54%
Arthritis 52%
Chronic kidney disease 39%
Heart failure 34%
COPD 25%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $137
$137 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $84
$84 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $28
$28 179 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $27
$27 — —
Crysvita
  • Kyowa Kirin, Inc. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

342 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record